Filters

Pp-229 manufacturers

Filters

1 products found

pp-229

Tablets

Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Focal Segmental Glomerulosclerosis (FSGS) / Clinical stage: Phase 3 / Modality: Small molecule CCR2 chemokine receptor antagonist / Mechanism & Target: CCR2 antagonist inhibiting immune infiltration / Route & form: Oral / Differentiation: First-in-class for FSGS; FDA confirmed proteinuria reduction as primary endpoint
Manufacturer #39436
Rare disease biopharmaceutical company developing enzyme enhancement and replacement therapies. Specializes in lysosomal storage disorders and rare renal conditions with high unmet need. Expands global portfolio through strategic acquisitions and late-stage development.
 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.